Controlled Attenuation Parameter (CAP): A noninvasive method for the detection of hepatic steatosis based on transient elastography

Liver International

Volumn 32, Issue 6, 2012, Pages 902-910

  Myers, Robert P ^a   Pollett, Aaron ^b   Kirsch, Richard ^c   Pomier Layrargues, Gilles ^c   Beaton, Melanie ^d   Levstik, Mark ^d   Duarte Rojo, Andres ^e   Wong, David ^e   Crotty, Pam ^a   Elkashab, Magdy ^f  

^a UNIVERSITY OF CALGARY   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF MONTREAL   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e TORONTO WESTERN HOSPITAL   (Canada)

^f Toronto Liver Centre   (Canada)

Author keywords

Biopsy; Elastography; Fatty liver; Steatosis

Indexed keywords

ADULT; ARTICLE; CONTROLLED ATTENUATION PARAMETER; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; ELASTOGRAPHY; FATTY LIVER; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY;

ADULT; BIOPSY; BODY MASS INDEX; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; ELASTICITY IMAGING TECHNIQUES; FATTY LIVER; FEMALE; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ONTARIO; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84861961483     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2012.02781.x     Document Type: Article

References (36)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
2. Negro F, Clement S. Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C. J Viral Hepat 2009; 16: 681-8.
3. O'Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatology 2010; 51: 307-28.
4. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
5. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 2009; 49: 1017-44.
6. Myers RP, Fong A, Shaheen AA. Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. Liver Int 2008; 28: 705-12.
7. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-906.
8. Castera L. Non-invasive diagnosis of steatosis and fibrosis. Diabetes Metab 2008; 34: 674-9.
9. Myers RP. Noninvasive diagnosis of nonalcoholic fatty liver disease. Ann Hepatol 2009; 8(Suppl. 1): S25-33.
10. Guha IN, Myers RP, Patel K, Talwalkar JA. Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve? Hepatology 2011; 54: 1454-62.
11. Mazhar SM, Shiehmorteza M, Sirlin CB. Noninvasive assessment of hepatic steatosis. Clin Gastroenterol Hepatol 2009; 7: 135-40.
12. Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis 2007;11:37-54, viii.
13. Schwenzer NF, Springer F, Schraml C, et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009; 51: 433-45.
14. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-13.
15. Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010; 36: 1825-35.
16. Myers RP, Pomier-Layrargues G, Kirsch R, et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012; 55: 199-208.
17. Bedogni G, Bellentani S, Miglioli L, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33.
18. Calori G, Lattuada G, Ragogna F, et al. Fatty liver index and mortality: the cremona study in the 15th year of follow-up. Hepatology 2011; 54: 145-52.
19. Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010; 42: 503-8.
20. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20: 15-20.
21. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
22. Lucidarme D, Foucher J, Le Bail B, et al. Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49: 1083-9.
23. Myers RP, Crotty P, Pomier-Layrargues G, et al. Prevalence, risk factors and causes of discordance in fibrosis staging by transient elastography and liver biopsy. Liver Int 2010; 30: 1471-80.
24. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-45.
25. Obuchowski NA, Goske MJ, Applegate KE. Assessing physicians' accuracy in diagnosing paediatric patients with acute abdominal pain: measuring accuracy for multiple diseases. Stat Med 2001; 20: 3261-78.
26. Lambert J, Halfon P, Penaranda G, et al. How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited. Clin Chem 2008; 54: 1372-8.
27. ®: validation in chronic hepatitis C. J Viral Hepat (in press).
28. El-Badry AM, Breitenstein S, Jochum W, et al. Assessment of hepatic steatosis by expert pathologists: the end of a gold standard. Ann Surg 2009; 250: 691-7.
29. Marsman H, Matsushita T, Dierkhising R, et al. Assessment of donor liver steatosis: pathologist or automated software? Hum Pathol 2004; 35: 430-5.
30. Younossi ZM, Gramlich T, Liu YC, et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol 1998; 11: 560-5.
31. DiDonato D, Brasaemle DL. Fixation methods for the study of lipid droplets by immunofluorescence microscopy. J Histochem Cytochem 2003; 51: 773-80.
32. Fukumoto S, Fujimoto T. Deformation of lipid droplets in fixed samples. Histochem Cell Biol 2002; 118: 423-8.
33. Strasberg SM, Howard TK, Molmenti EP, Hertl M. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology 1994; 20: 829-38.
34. Poynard T, Ratziu V, Naveau S, et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005; 4: 10.
35. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50.
36. Palmentieri B, de Sio I, La Mura V, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis 2006; 38: 485-9.